Skip to content

Snowden Capital Advisors LLC: CCEP position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Snowden Capital Advisors LLC on CCEP, newest first. How the timeline and the estimate are built.

Snowden Capital Advisors LLC held 2,133 CCEP shares at 2026-06-30 per its 13F-HR filed 2026-08-13.

the latest 13F is the newest step

  1. period ended2026-06-30
    13F 2,133 shares
    Change vs previous 13F -146 shares

    0.01% of the 13F portfolio, value $213,449.

    13F-HR 0001172661-26-003380 filed by Snowden Capital Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2026-03-31
    13F 2,279 shares
    Change vs previous 13F +39 shares

    0.01% of the 13F portfolio, value $206,637.

    13F-HR 0001172661-26-002018 filed by Snowden Capital Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-12-31
    13F 2,240 shares
    Change vs previous 13F +2,240 shares

    0.01% of the 13F portfolio, value $203,168.

    13F-HR 0001172661-26-000888 filed by Snowden Capital Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2024-12-31
    13F 0 shares
    Change vs previous 13F -3,070 shares

    13F-HR 0001172661-25-000945 filed by Snowden Capital Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

    Exited: the 13F for this period no longer lists the position.

  5. period ended2024-09-30
    13F 3,070 shares
    Change vs previous 13F not available

    0.01% of the 13F portfolio, value $241,763.

    13F-HR 0001172661-24-005281 filed by Snowden Capital Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).